Amgen And AbbVie In Legal Settlement


According to the two, AbbVie will grant a patent license for use and sale of the compound worldwide, on a country-by-country basis. As a result of the settlement, Amgen said it expects to launch its product in Europe in October of 2018, and its product for the United States in 2023.